Clinical Research Directory

Type 2 Inflammation in Adults With Cystic Fibrosis

Sponsor: University of Virginia

Summary

The goal of this observational study is to better understand why some adults with cystic fibrosis (CF) continue to have repeated pulmonary exacerbations, or episodes of worsening respiratory symptoms, despite treatment with highly effective CFTR modulator therapy. The study will focus on whether a type of inflammation called type 2 (T2) inflammation may contribute to these pulmonary exacerbations. The main questions this study aims to answer are: Are signs of T2 inflammation more common in adults with CF who have frequent pulmonary exacerbations? Are there differences in inflammation in the nose and airways between people who have frequent pulmonary exacerbations and those who do not? How do immune cells and inflammation change during a pulmonary exacerbation? Participants will: Allow researchers to collect information about their CF and pulmonary exacerbations from their medical records. Complete questionnaires about respiratory and sinus symptoms and quality of life. Provide research blood samples, samples from inside the nose, and exhaled breath condensate. Be followed for up to approximately 3 years, with additional research samples collected during qualifying pulmonary exacerbations when feasible. Participants will continue to receive their usual CF medical care. No experimental medications or treatments will be given as part of this study.

Official title: Importance of Type 2 Inflammation in Adults With Cystic Fibrosis and Recurrent Pulmonary Exacerbations

Key Details

Conditions